AR023806A1 - USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS - Google Patents

USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS

Info

Publication number
AR023806A1
AR023806A1 ARP000102059A ARP000102059A AR023806A1 AR 023806 A1 AR023806 A1 AR 023806A1 AR P000102059 A ARP000102059 A AR P000102059A AR P000102059 A ARP000102059 A AR P000102059A AR 023806 A1 AR023806 A1 AR 023806A1
Authority
AR
Argentina
Prior art keywords
mixture
compositions
profilaxis
procedures
manufacture
Prior art date
Application number
ARP000102059A
Other languages
Spanish (es)
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of AR023806A1 publication Critical patent/AR023806A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a mezclas de péptidos sintéticos que producen inmunidad de células T, para el uso en vacunas contra el cáncer y composiciones parael tratamiento contra el cáncer.This refers to mixtures of synthetic peptides that produce T-cell immunity, for use in cancer vaccines and compositions for cancer treatment.

ARP000102059A 1999-04-30 2000-04-28 USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS AR023806A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19992102A NO309798B1 (en) 1999-04-30 1999-04-30 Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition

Publications (1)

Publication Number Publication Date
AR023806A1 true AR023806A1 (en) 2002-09-04

Family

ID=19903274

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102059A AR023806A1 (en) 1999-04-30 2000-04-28 USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS

Country Status (7)

Country Link
EP (1) EP1173199A1 (en)
JP (1) JP2002543149A (en)
AR (1) AR023806A1 (en)
AU (1) AU4438900A (en)
CA (1) CA2372187A1 (en)
NO (1) NO309798B1 (en)
WO (1) WO2000066153A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836684B1 (en) * 2002-03-04 2004-12-17 Inst Nat Sante Rech Med RAS MUTED PEPTIDES AND THEIR USE IN IMMUNOTHERAPY
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CN104147597A (en) * 2002-12-16 2014-11-19 全球免疫股份有限公司 Yeast-based vaccines as immunotherapy
TW200806789A (en) 2006-03-27 2008-02-01 Globeimmune Inc RAS mutation and compositions and methods related thereto
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
MX2012002639A (en) * 2009-09-03 2012-03-14 Pfizer Vaccines Llc Pcsk9 vaccine.
KR102095670B1 (en) 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 Compositions and methods of identifying tumor specific neoantigens
CN102060929A (en) * 2010-06-07 2011-05-18 夏书奇 T-cell immune balance peptide
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3363457A1 (en) * 2013-12-09 2018-08-22 Targovax Asa A peptide mixture
KR20160101073A (en) 2013-12-20 2016-08-24 더 브로드 인스티튜트, 인코퍼레이티드 Combination therapy with neoantigen vaccine
AU2015257774B2 (en) * 2014-05-06 2018-12-20 Targovax Solutions AS Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
CN116196401A (en) 2015-05-20 2023-06-02 博德研究所 Consensus neoantigens
BR112017025728A2 (en) * 2015-06-16 2018-08-07 Targovax Asa mutant fragments of ras protein
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3051252A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
CN110709094A (en) * 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 KRAS peptide vaccine compositions and methods of use thereof
TW201930340A (en) 2017-12-18 2019-08-01 美商尼恩醫療公司 Neoantigens and uses thereof
CN114681600A (en) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 Universal polypeptide vaccine and application thereof in preparation of medicine for treating/preventing pancreatic cancer
WO2020145222A1 (en) * 2019-01-07 2020-07-16 地方独立行政法人神奈川県立病院機構 Novel neoantigens and cancer immunotherapy using same
IL266728B (en) * 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutated neopeptides
CN115484971A (en) * 2020-02-19 2022-12-16 艾琳治疗公司 Protein targeting molecules
KR20220143702A (en) * 2020-02-19 2022-10-25 에린 테라퓨틱스 Molecules targeting the RAS protein
WO2022219152A1 (en) * 2021-04-16 2022-10-20 Oblique Therapeutics Ab Kras antibodies
WO2024112821A1 (en) * 2022-11-22 2024-05-30 Elixirgen Therapeutics, Inc. Antigens for cancer immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
WO1997040156A1 (en) * 1996-04-19 1997-10-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
GB9620350D0 (en) * 1996-09-30 1996-11-13 Maudsley David J Cancer vaccine
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer

Also Published As

Publication number Publication date
NO992102D0 (en) 1999-04-30
EP1173199A1 (en) 2002-01-23
JP2002543149A (en) 2002-12-17
WO2000066153A1 (en) 2000-11-09
AU4438900A (en) 2000-11-17
CA2372187A1 (en) 2000-11-09
NO992102L (en) 2000-10-31
NO309798B1 (en) 2001-04-02

Similar Documents

Publication Publication Date Title
AR023806A1 (en) USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS
ES2167061T3 (en) DOSAGE FORMS TO IMPROVE ERECTILE DYSFUNCTION IN MALE SEX PATIENTS.
AR033808A1 (en) A TOPICAL COMPOSITION OF LOCAL ANESTHESIA AND THE PATCHES AND CONTAINERS CONTAINING IT
ES2161085T3 (en) FORMULATIONS CONTAINING OXALIPLATIN.
CR6326A (en) PHARMACEUTICAL FORMULATIONS OF CONTROLLED LIBERATION
ES2162319T3 (en) USE OF THE CLIOQUINOL CHELATING AGENT FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
ES2134797T3 (en) THERAPEUTICALLY USEFUL PEPTIDES AND PEPTIDES FRAGMENTS.
BRPI0415007A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
PA8479201A1 (en) DERIVATIVES OF HYDROXY ACID-HYDROXAMIC PIPECOLATE
MX9304837A (en) PEPTIDES ABLE TO INHIBIT THE ACTIVITY OF HIV PROTEASE, ITS PREPARATION AND ITS THERAPEUTIC USE.
ES2102921T3 (en) USE OF DERIVATIVES OF THE STIMULATING HORMONE OF ALPHA-TYPE MELANOCITES TO STIMULATE HAIR GROWTH.
AR042051A1 (en) COMBINED TREATMENT AGAINST CANCER WITH AN ANTI-CANCERIGENE COMPOUND ACTIVATED BY GLUTATIONA S- TRANSFERASA (GST) AND OTHER TREATMENT AGAINST CANCER
CU20210003A7 (en) A LIPOSOMAL PHARMACEUTICAL PREPARATION OF MITOXANTRONE USEFUL IN THE TREATMENT OF NON-HODGKIN LYMPHOMA
AR006401A1 (en) PIRROLOPYROLONE COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND IN THERAPY, PROCESSES FOR ITS PREPARATION AND INTERMEDIARY COMPOUNDS FOR SUCH PROCESSES.
AR022589A1 (en) A CAPSULE THAT INCLUDES A SPONTANELY DISPERSABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, A SPONTANELY DISPERSABLE PHARMACEUTICAL COMPOSITION FOR THE ORAL ADMINISTRATION AND THE USE FOR THE PREPARATION OF A TREATMENT MEDICATION
AR043071A1 (en) USE OF MACROLIDES FOR THE TREATMENT OF CANCER AND MACULAR DEGENERATION AND A PHARMACEUTICAL COMPOSITION
HK1068606A1 (en) Novel aminobenzoephenones
ES2188995T3 (en) USE OF AN INHIBITOR OF THE H +, K + -ATPASA IN THE TREATMENT OF NASAL POLYPS.
CO5160272A1 (en) COMBINATION OF CERIVASTATIN AND FIBRATES
AR025060A1 (en) PHARMACEUTICAL FORMULATIONS IN HYDROXYPROPILMETILCELLULOSE CAPSULES
AR014640A1 (en) AN INHIBITING PHARMACEUTICAL COMPOSITION OF METASTASIC DISSEMINATION DURING THE SURGERY OF A CANCEROUS TUMOR, A PREPARATION PROCEDURE AND A KIT FOR AN INJECTABLE FORMULATION.
AR036321A1 (en) METHOD AND PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF LATE APPEARANCE DYSCINESIA.
ES2052484T1 (en) N- (5-TIOXO-L-PROLIL) -L-CYSTEINE, ITS DERIVATIVES, PROCEDURES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
CY1108785T1 (en) STABLE MEDICINAL GEL DICLOFENAC NA
AR034142A1 (en) A PHARMACEUTICAL COMPOSITION, METHOD FOR MANUFACTURING A MEDICINAL BASED ON SUCH COMPOSITION AND USE OF THE COMPOSITION